STAAR Surgical reported a strong second quarter: Net sales more than doubled to $93.5 million, while the company returned to profitability with $8.1 million in net income and $20 million in adjusted EBITDA. China drove growth through EVO+ adoption: China sales rose more than 100% to $52.3 million, with EVO+ approaching one-third of unit volume and demand appearing to reflect end-market consumption rather than distributor inventory buildup. The company strengthened its financial position and outlook: STAAR ended the quarter with $181.5 million in cash and no debt, expects significant second-half free cash flow and more than $200 million in cash at year-end, while targeting full Swiss manufacturing for China-bound products by the end of 2026.
Top 4 Stocks With Notable Insider Buying STAAR Surgical (NASDAQ:STAA) reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance. The prior-year quarter included minimal shipments to China while distributors worked through excess inventory, according to Executive Vice President and Chief Financial Officer Deborah Andrews. Excluding China, second-quarter sales were $41.2 million, an increase of 6% year over year. → AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be Star Surgical Shines as U.S.
Outlook Improves for 2024 The company also returned to profitability, reporting net income of $8.1 million, or $0.16 per diluted share, compared with a net loss of $16.8 million, or $0.34 per diluted share, in the prior-year period. Adjusted EBITDA was $20 million, compared with an adjusted EBITDA loss of $14.8 million a year earlier. China sales rose more than 100% year over year and increased 10% sequentially to $52.3 million.
Foust said the company saw no evidence of inventory buildup at distributors or hospitals, which he said supports the view that demand, rather than channel inventory, is driving growth. → Nebius' Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand STAAR attributed its China performance in part to the launch of EVO+, its lens-based refractive surgery offering. Foust said EVO+ adoption exceeded the company's expectations and had outpaced its supply capabilities. By the end of the second quarter, EVO+ represented "probably close to a third" of unit volume in China, he said.
Foust said the company continues to receive a premium price for EVO+ and that customers and patients have not resisted that pricing. He also said STAAR believes it is gaining share in a refractive market that remains uneven, with laser-based procedures facing pressure in China and other markets. → Apple's Next iPhone Could Test How Much Pricing Power Is Left "We're definitely getting a lift from the EVO+ rollout," Foust said, adding that patients and surgeons are responding to the lens-based procedure's reversibility and its preservation of corneal tissue. Management said China's seasonal pattern has shifted, with the first and second quarters emerging as the company's strongest periods because of Chinese New Year, military recruitment-related procedures shifting earlier in the year, and summer demand.
STAAR expects third-quarter China revenue to be moderately lower sequentially than the second quarter, while still growing year over year when compared with an adjusted prior-year base. The fourth quarter is expected to remain seasonally softer, though management also expects year-over-year growth. Foust cautioned investors that third-quarter 2025 revenue included $25.9 million related to a 2024 order.
Extract — continue reading at the source.
